This partnership is a patient advocacy and care-enabling initiative, not a commercial or clinical catalyst. Traders should monitor for future updates on pociredir’s clinical development or regulatory progress as the primary value drivers. No immediate financial impact is expected.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 19 $7.04entry
- T+1 · 8mo ago −3.84%α −2.09% · $6.77
- T+5 · 8mo ago −1.42%α +0.79% · $6.94
- T+20 · 7mo ago +17.76%α +10.13% · $8.29
- T+60 · 5mo ago −50.14%α −64.49% · $3.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fulcrum Therapeutics (FULC) announced a partnership with MedicAlert Foundation and the Sickle Cell Disease Association of America (SCDAA) to expand access to emergency medical information for sickle cell disease (SCD) patients via MedicAlert’s Smart Medical ID Cards. The program links patient-specific care plans to QR codes, enabling faster clinical decisions during ED visits. Fulcrum is funding the expansion but no financial terms were disclosed.
Key Facts
- Fulcrum Therapeutics partnered with MedicAlert and SCDAA to expand emergency care access for sickle cell disease patients.
- The program provides patients with a MedicAlert Smart Medical ID Card that links to a digital health profile containing pain plans, medications, allergies, and hematologist contacts.
- No financial terms, dollar amounts, or share impacts were disclosed.
- This is a non-commercial, patient-support initiative aimed at improving care coordination, not a product launch or regulatory event.
- Fulcrum’s lead candidate, pociredir, remains in clinical development for SCD.
Financial Impact
Unknown, no financial terms disclosed
Risk Factors
- No measurable financial or clinical benefit to Fulcrum from this program
- Potential for increased operating expenses if funding is significant
- No assurance of improved patient outcomes or adoption in emergency settings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258908 |
Track record
23 reports on FULC
6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
- Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers